FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Patel Sujal M
2. Issuer Name and Ticker or Trading Symbol

Nautilus Biotechnology, Inc. [ NAUT ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    __X__ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
CEO, President, and Secretary
(Last)          (First)          (Middle)

C/O NAUTILUS BIOTECHNOLOGY, INC., 2701 EASTLAKE AVENUE EAST
3. Date of Earliest Transaction (MM/DD/YYYY)

11/30/2021
(Street)

SEATTLE, WA 98102
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/30/2021  P  161978 A$4.7215 (1)9776366 D  
Common Stock 12/1/2021  P  88022 A$4.7306 (2)9864388 D  
Common Stock         5280476 I By PFV I, LLC (3)
Common Stock         1814035 I By Sujal Patel 2020 Children's Trust, u/a/d December 3, 2020 (4)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares

Explanation of Responses:
(1) Represents the weighted average share price of an aggregate total of 161,978 shares purchased in the price range of $4.48 to $4.85 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
(2) Represents the weighted average share price of an aggregate total of 88,022 shares purchased in the price range of $4.44 to $5.00 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
(3) Shares held by PFV I, LLC. The reporting person is the manager of PFV I, LLC.
(4) Shares held by Sujal Patel 2020 Children's Trust, u/a/d December 3, 2020 (the "Patel Trust"). The reporting person and the reporting person's spouse are the trustees of the Patel Trust.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Patel Sujal M
C/O NAUTILUS BIOTECHNOLOGY, INC.
2701 EASTLAKE AVENUE EAST
SEATTLE, WA 98102
XXCEO, President, and Secretary

Signatures
/s/ Matthew B. Murphy, as Attorney-in-Fact12/1/2021
**Signature of Reporting PersonDate

ARYA Sciences Acquistion... (NASDAQ:ARYA)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more ARYA Sciences Acquistion... Charts.
ARYA Sciences Acquistion... (NASDAQ:ARYA)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more ARYA Sciences Acquistion... Charts.